


The Fund aims to achieve long term capital growth primarily through investment in a focussed portfolio of equities issued by companies established in any country and in derivatives, the underlying assets of which are equities issued by companies established in any country.
| Name | % Net Assets |
|---|---|
| Altria Group Inc. | 2.3% |
| Sanofi-Synthelabo | 2.2% |
| British American Tobacco | 2.1% |
| Anheuser-Busch Inbev | 2.1% |
| CBS Corp | 2.0% |
| Amerisourcebergen Corp. | 2.0% |
| Telstra Corp. Ltd. | 2.0% |
| Unitedhealth Group Inc. | 2.0% |
| Novartis | 2.0% |
| Oracle Corp. | 2.0% |
| Key | % Net Assets |
|---|---|
| 2.3% | |
| 2.2% | |
| 2.1% | |
| 2.1% | |
| 91.3% |
| Date | 07-Oct-2022 |
|---|---|
| NAV | 338.49p |
| Currency | GBP |
| Change | 3.41p |
| % | 1.02% |
| YTD change | 338.49p |
| YTD % | n/a |
| Fund Inception | 24/02/1998 |
|---|---|
| Fund Manager | n/a |
| TER | 1.11 (28-Feb-2009) |
| Minimum Investment | |
|---|---|
| Initial | £1000000 |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | n/a |
| Annual Mang't | 0.75% |
| Exit | n/a |
| Name | % |
|---|---|
| No risk data available. | |
You are here: research